Now in its 11th year, SMi's annual Pain Therapeutic conference series has gone from strength to strength. This year's event seeks to address the current issues facing the Clinical R&D field of Pain drug development, and the challenges when taking a new drug from pre- to post-clinical trials.
Pain affects all of us some of the time, and many of us all the time. Yet, the pharmacologic treatments available to alleviate pain have changed little in the last 50 years. Those who suffer from acute pain originating in the peripheral nervous system have the best chances of finding relief, while others suffering chronic neuropathic pain must often settle for partial or even minimal relief.
In addition the current models and theories of pain and its mechanisms have failed to yeild significantly new therapeutics over recent years.